+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Bronchiolitis Obliterans Syndrome Market by Disease Type, Treatment Type, End-User, Drug Type, Route of Administration, Patient Demographics, Diagnosis Method - Global Forecast 2025-2030- Product Image
Bronchiolitis Obliterans Syndrome Market by Disease Type, Treatment Type, End-User, Drug Type, Route of Administration, Patient Demographics, Diagnosis Method - Global Forecast 2025-2030- Product Image
Sale

Bronchiolitis Obliterans Syndrome Market by Disease Type, Treatment Type, End-User, Drug Type, Route of Administration, Patient Demographics, Diagnosis Method - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 191 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6011463
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bronchiolitis Obliterans Syndrome Market grew from USD 67.53 million in 2023 to USD 73.25 million in 2024. It is expected to continue growing at a CAGR of 8.37%, reaching USD 118.54 million by 2030.

Bronchiolitis Obliterans Syndrome (BOS) is a severe, chronic lung condition that primarily affects individuals following lung transplantation and can also occur due to toxic inhalants or infections. The scope of research and market development for BOS involves pharmaceuticals, medical devices, and therapies aimed at prevention, early diagnosis, and treatment. The rising prevalence of lung transplants and environmental factors has necessitated expanding BOS management solutions. The primary end-use scope includes healthcare providers like hospitals, specialty clinics, and research organizations. Critical growth factors in the BOS market include increased awareness of pulmonary conditions, advances in biopharmaceuticals, and the growing incidence of respiratory syndromes. Potential opportunities lie in developing novel therapeutics and improved diagnostic techniques leveraging biotechnology and artificial intelligence. Firms are encouraged to invest in personalized medicine approaches and robust clinical trials to refine treatment efficacy and safety profiles. Limitations in the market consist of high costs associated with treatment, limited availability of transplant organs, and stringent regulatory frameworks, which can restrict the adoption of new solutions. Additional challenges include inherent complexities in BOS pathophysiology and a lack of consensus on standardized treatment protocols. To spur innovation, research should focus on identifying biomarkers for early diagnosis, developing non-invasive monitoring tools, and enhancing immunosuppressive therapies with minimized side effects. Exploring new avenues like cell-based therapies and gene editing offers promising potential to revolutionize BOS management. Overall, the market is characterized by a high degree of competitiveness and significant R&D investment. Strategic partnerships and cross-collaboration among biotechnology firms, research institutes, and healthcare providers are imperative for market expansion. Innovators who can efficiently navigate regulatory landscapes and meet unmet medical needs will likely secure substantial market shares and drive the industry's future trajectory.

Understanding Market Dynamics in the Bronchiolitis Obliterans Syndrome Market

The Bronchiolitis Obliterans Syndrome Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Advancements in medical technology and treatments leading to better management of bronchiolitis obliterans syndrome
    • Increasing prevalence of lung diseases contributing to higher demand for bronchiolitis obliterans syndrome therapies
    • Rising healthcare expenditure and government funding boosting research and development in bronchiolitis obliterans
    • Growing awareness among healthcare professionals and patients about bronchiolitis obliterans syndrome and its treatments
  • Market Restraints
    • Limited research funding and investment in bronchiolitis obliterans syndrome hindering advancements
  • Market Opportunities
    • Emerging advanced therapeutic approaches to treat bronchiolitis obliterans syndrome patients
    • Growing research and development activities for innovative bronchiolitis obliterans syndrome treatments
    • Expanding public awareness campaigns to enhance early detection of bronchiolitis obliterans syndrome
  • Market Challenges
    • Stringent regulatory approval processes delaying new treatments for bronchiolitis obliterans syndrome

Exploring Porter’s Five Forces for the Bronchiolitis Obliterans Syndrome Market

Porter’s Five Forces framework further strengthens the insights of the Bronchiolitis Obliterans Syndrome Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Bronchiolitis Obliterans Syndrome Market

External macro-environmental factors deeply influence the performance of the Bronchiolitis Obliterans Syndrome Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Bronchiolitis Obliterans Syndrome Market

The Bronchiolitis Obliterans Syndrome Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Bronchiolitis Obliterans Syndrome Market

The Bronchiolitis Obliterans Syndrome Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Bronchiolitis Obliterans Syndrome Market

The Bronchiolitis Obliterans Syndrome Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bronchiolitis Obliterans Syndrome Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, Chiesi Farmaceutici S.p.A., Eli Lilly and Company, FibroGen, Inc., Gilead Sciences, GlaxoSmithKline plc, Insmed Incorporated, Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi, Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Theravance Biopharma.

Market Segmentation & Coverage

This research report categorizes the Bronchiolitis Obliterans Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Disease Type
    • Bronchiolitis Obliterans Syndrome
    • Non-Bronchiolitis Obliterans Syndrome
  • Treatment Type
    • Non-Pharmacological Treatment
      • Oxygen Therapy
      • Pulmonary Rehabilitation
      • Surgical Therapy
    • Pharmacological Treatment
      • Antibiotics
      • Corticosteroids
      • Immunosuppressive Agents
  • End-User
    • Ambulatory Surgical Centers
    • Homecare Settings
    • Hospitals
    • Specialty Clinics
  • Drug Type
    • Branded
    • Generic
  • Route of Administration
    • Inhalation
    • Intravenous
    • Oral
  • Patient Demographics
    • Adult
    • Geriatric
    • Pediatric
  • Diagnosis Method
    • Blood Tests
    • High-Resolution CT Scan
    • Lung Biopsy
    • Pulmonary Function Tests
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Advancements in medical technology and treatments leading to better management of bronchiolitis obliterans syndrome
5.1.1.2. Increasing prevalence of lung diseases contributing to higher demand for bronchiolitis obliterans syndrome therapies
5.1.1.3. Rising healthcare expenditure and government funding boosting research and development in bronchiolitis obliterans
5.1.1.4. Growing awareness among healthcare professionals and patients about bronchiolitis obliterans syndrome and its treatments
5.1.2. Restraints
5.1.2.1. Limited research funding and investment in bronchiolitis obliterans syndrome hindering advancements
5.1.3. Opportunities
5.1.3.1. Emerging advanced therapeutic approaches to treat bronchiolitis obliterans syndrome patients
5.1.3.2. Growing research and development activities for innovative bronchiolitis obliterans syndrome treatments
5.1.3.3. Expanding public awareness campaigns to enhance early detection of bronchiolitis obliterans syndrome
5.1.4. Challenges
5.1.4.1. Stringent regulatory approval processes delaying new treatments for bronchiolitis obliterans syndrome
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Bronchiolitis Obliterans Syndrome Market, by Disease Type
6.1. Introduction
6.2. Bronchiolitis Obliterans Syndrome
6.3. Non-Bronchiolitis Obliterans Syndrome
7. Bronchiolitis Obliterans Syndrome Market, by Treatment Type
7.1. Introduction
7.2. Non-Pharmacological Treatment
7.2.1. Oxygen Therapy
7.2.2. Pulmonary Rehabilitation
7.2.3. Surgical Therapy
7.3. Pharmacological Treatment
7.3.1. Antibiotics
7.3.2. Corticosteroids
7.3.3. Immunosuppressive Agents
8. Bronchiolitis Obliterans Syndrome Market, by End-User
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Homecare Settings
8.4. Hospitals
8.5. Specialty Clinics
9. Bronchiolitis Obliterans Syndrome Market, by Drug Type
9.1. Introduction
9.2. Branded
9.3. Generic
10. Bronchiolitis Obliterans Syndrome Market, by Route of Administration
10.1. Introduction
10.2. Inhalation
10.3. Intravenous
10.4. Oral
11. Bronchiolitis Obliterans Syndrome Market, by Patient Demographics
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. Bronchiolitis Obliterans Syndrome Market, by Diagnosis Method
12.1. Introduction
12.2. Blood Tests
12.3. High-Resolution CT Scan
12.4. Lung Biopsy
12.5. Pulmonary Function Tests
13. Americas Bronchiolitis Obliterans Syndrome Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Bronchiolitis Obliterans Syndrome Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Bronchiolitis Obliterans Syndrome Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2023
16.2. FPNV Positioning Matrix, 2023
16.3. Competitive Scenario Analysis
16.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. BRONCHIOLITIS OBLITERANS SYNDROME MARKET RESEARCH PROCESS
FIGURE 2. BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 15. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
FIGURE 17. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2023 VS 2030 (%)
FIGURE 19. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 23. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 28. BRONCHIOLITIS OBLITERANS SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 29. BRONCHIOLITIS OBLITERANS SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. BRONCHIOLITIS OBLITERANS SYNDROME MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. BRONCHIOLITIS OBLITERANS SYNDROME MARKET DYNAMICS
TABLE 7. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY BRONCHIOLITIS OBLITERANS SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-BRONCHIOLITIS OBLITERANS SYNDROME, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PULMONARY REHABILITATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SURGICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY IMMUNOSUPPRESSIVE AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY HIGH-RESOLUTION CT SCAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY LUNG BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PULMONARY FUNCTION TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 70. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 71. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 72. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 73. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 74. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 76. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 78. CANADA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 79. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 80. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 81. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 82. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 83. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 85. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 86. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 87. MEXICO BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 98. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 99. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 100. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 101. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 102. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 104. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 105. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 106. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 107. ASIA-PACIFIC BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 108. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 109. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 110. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 111. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 112. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 113. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 114. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 115. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 116. AUSTRALIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 117. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 118. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 119. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 120. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 121. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 122. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 123. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 125. CHINA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 126. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 127. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 128. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 129. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 130. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 131. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 132. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 134. INDIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 135. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 136. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 137. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 138. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 139. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 140. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 141. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 143. INDONESIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 144. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 145. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 146. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 147. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 148. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 149. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 150. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 152. JAPAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 153. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 154. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 155. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 156. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 157. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 159. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 161. MALAYSIA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 162. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 163. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 164. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 165. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 166. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 167. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 168. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 169. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 170. PHILIPPINES BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 171. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 172. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 173. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 174. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 175. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 176. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 177. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 179. SINGAPORE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 180. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 181. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 182. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 183. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 184. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 185. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 186. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 187. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 188. SOUTH KOREA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 189. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 190. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 191. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 192. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 193. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 194. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 195. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 197. TAIWAN BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 198. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 199. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 200. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 201. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 202. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 203. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 204. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 205. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 206. THAILAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 207. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 208. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 209. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 210. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 211. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 212. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 213. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 215. VIETNAM BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 226. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 227. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 228. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 229. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 230. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 231. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 232. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 234. DENMARK BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 235. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 236. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 237. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 238. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 239. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 240. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 241. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 243. EGYPT BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 244. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 245. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 246. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 247. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 248. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 249. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 250. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 252. FINLAND BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 253. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 254. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 255. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 256. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 257. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 258. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 259. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 261. FRANCE BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 262. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 263. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 264. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 265. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 266. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 267. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 268. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 269. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 270. GERMANY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 272. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 273. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 274. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 275. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 276. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 277. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 279. ISRAEL BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 280. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 281. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 282. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY NON-PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 283. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, 2018-2030 (USD MILLION)
TABLE 284. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 285. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 286. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 287. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 288. ITALY BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DIAGNOSIS METHOD, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS BRONCHIOLITIS OBLITERANS SYNDROME MARKET SI

Companies Mentioned

The leading players in the Bronchiolitis Obliterans Syndrome market, which are profiled in this report, include:
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Chiesi Farmaceutici S.p.A.
  • Eli Lilly and Company
  • FibroGen, Inc.
  • Gilead Sciences
  • GlaxoSmithKline plc
  • Insmed Incorporated
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi
  • Sunovion Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages191
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 73.25 Million
Forecasted Market Value ( USD ) by 2030 $ 118.54 Million
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Bronchiolitis Obliterans Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Bronchiolitis Obliterans Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 134 Pages
  • Global
From
Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2024 - Product Image

Bronchiolitis Obliterans Syndrome - Pipeline Insight, 2024

  • Clinical Trials
  • 60 Pages
  • Global
From
Bronchiolitis - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Bronchiolitis - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Bronchiolitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 - Product Image

Bronchiolitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • Report
  • 138 Pages
  • Global
From
Clinical Manifestations and Assessment of Respiratory Disease. Edition No. 9 - Product Image

Clinical Manifestations and Assessment of Respiratory Disease. Edition No. 9

  • Book

About the Market

Bronchiolitis Obliterans Syndrome (BOS) is a rare and serious lung disease caused by an inflammatory response to inhaled toxins. It is characterized by the narrowing of the bronchioles, leading to difficulty breathing and other respiratory symptoms. Treatment for BOS is limited to supportive care, such as oxygen therapy, and medications to reduce inflammation and improve airway function. The BOS drug market is a small but growing segment of the respiratory drug market. It is composed of a variety of medications, including corticosteroids, bronchodilators, and immunosuppressants. These drugs are used to reduce inflammation, improve airway function, and reduce the risk of further damage to the lungs. The BOS drug market is highly competitive, with several major pharmaceutical companies competing for market share. Companies such as GlaxoSmithKline, AstraZeneca, and Novartis are all active in the BOS drug market, offering a range of medications to treat the condition. Other companies, such as Merck, Pfizer, and Sanofi, are also involved in the development of new treatments for BOS. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.